The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted ...

Aurobindo Pharma's CuraTeQ Biologics receives marketing authorization for Zefylti filgrastim biosimilar in the UK and EU.

The United States is advising travellers aged 60 and up to hold off on getting the chikungunya vaccine while it looks into reports of possible side effects.

EMERYVILLE, Calif. , May 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator ...

Key messagesGREG is a five-year, 26.2 million euros initiative that unites 29 partner organisations to advance Real-World ...

OLPRUVA: 5 new patient enrollment forms were received in Q1 2025, bringing the total from initial product availability in July 2023, and including Zevra's promotion of OLPRUVA since late January 2024, ...

Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

The European Medicines Agency (EMA) has approved Moleculin Biotech’s clinical trial application (CTA) for a pivotal, ...

Investing.com -- Shares of Regenxbio Inc . (NASDAQ: RGNX) climbed 7.2% in premarket trading after the company announced the U.S. Food and Drug Administration (FDA) has accepted for priority review its ...

Ixchiq is the first preventive vaccine against the chikungunya virus authorised in Europe and the US. Among the adverse events included the death of adults aged 62 and 89 years. However, the exact ...